Vitamin D 3 as an add-on treatment for multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials

João Vitor Mahler,Marina Solti,Samira Luísa Apóstolos-Pereira,Tarso Adoni,Guilherme Diogo Silva,Dagoberto Callegaro

DOI: https://doi.org/10.1016/j.msard.2024.105433

IF: 4.808

2024-01-07

Multiple Sclerosis and Related Disorders

Abstract:Background Vitamin D deficiency has been linked to a higher risk of multiple sclerosis (MS) and disease progression. However, the efficacy of vitamin D 3 as an adjuvant therapy for MS remains a controversial topic. Objective To perform a systematic review and meta-analysis of randomized controlled trials to assess the impact of adjunct high-dose vitamin D 3 on clinical and radiological outcomes. Methods PubMed, Embase, and Cochrane Library were searched for trials published until December 18th, 2022. Authors independently selected randomized controlled trials involving patients with MS, with an intervention group receiving high dose (≥1000 IU/day) cholecalciferol and reporting clinical or radiological outcomes. Authors independently extracted data and assessed the risk of bias using a standardized, pilot-tested form. The meta-analysis was conducted using RStudio for EDSS at the last follow-up, ARR, and new T2 lesion count. Results We included 9 studies with 867 participants. No significant reduction of EDSS (MD = 0.02, CI 95% [-0.37; 0.41], p = 0.91), ARR (MD -0.03, CI 95% [-0.08; 0.02], p = 0.26), or new T2 lesions (MD -0.59, CI 95% [-1.24;0.07], p = 0.08) was observed at 6-24 months. We found no evidence of publication bias. Conclusion The findings of this meta-analysis strengthen current evidence that vitamin D 3 supplementation has no significant impact on clinical outcomes in patients with MS. However, the non-significant reduction of new T2 lesions could precede long-term clinical benefits and should be validated in additional studies.

clinical neurology